Breakthroughs, discoveries, and DIY tips sent every weekday. Terms of Service and Privacy Policy. Researchers at Oxford announced today that a nasal spray version of ...

An intranasal formulation of AstraZeneca's widely-used COVID-19 vaccine Vaxzevria has failed at the first hurdle, after results from a phase 1 trial found it was unable to stimulate a strong ...

The U.S. FDA has given the green light for AstraZeneca's FluMist nasal spray vaccine to be self-administered or administered by a caregiver. The approval means that FluMist, which is made by the ...

Keith Speights: The University of Oxford recently announced that it's testing a nasal spray version of the COVID vaccine that it developed along with AstraZeneca, ticker for AstraZeneca is AZN.

AstraZeneca Plc’s ambitions for developing an easier formulation of its Covid-19 vaccine -- one that might help curb contagion as well -- suffered a setback Monday as the nasal spray failed in ...

The US Food and Drug Administration is reviewing an application for the nasal spray flu vaccine FluMist to be able to be self-administered at home, drugmaker AstraZeneca said Tuesday. The vaccine ...

Oct 11 (Reuters) - Attempts by Oxford University researchers and AstraZeneca Plc (AZN.L ... across the world have placed high hopes on nasal spray vaccines against the coronavirus because ...

The University of Oxford has begun a phase 1 clinical trial of a nasal spray formulation of its AstraZeneca-partnered COVID-19 vaccine. A clutch of biotechs is working on next-generation nasal ...

Earlier this week, AstraZeneca announced that the FDA is reviewing an application for its nasal spray flu vaccine FluMist, which would become the first self-administered flu vaccine available ...

AstraZeneca is seeking FDA approval for its nasal spray flu vaccine, FluMist, for self-administration, at home. If granted FDA approval, FluMist will be the first and only at-home, self ...